E
SWTX

Ergoteles’s SpringWorks Therapeutics SWTX Stock Holding History

Ergoteles’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-14,700
Closed -$385K – 748
2023
Q2 		$385K Sell
14,700
-6,934
-32% -$182K 0.02% 708
2023
Q1 		$557K Buy
+21,634
New +$632K 0.02% 701

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ergoteles's SWTX Position: Q3 2023 in Review

Ergoteles sold out of SpringWorks Therapeutics (SWTX) in Q3 2023, closing a stake of 14,700 shares — an estimated $385K sold.

Ergoteles first reported a position in SWTX in Q1 2023 and held it in 2 quarters. The position peaked at $557K in Q1 2023. 147 funds tracked by Wall St. Rank hold SWTX as of Q3 2023.

  • Ergoteles reported no remaining SpringWorks Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 14,700 SpringWorks Therapeutics shares in Q3 2023, an estimated $385K.
  • Ergoteles first reported a position in SpringWorks Therapeutics in Q1 2023 and held it in 2 quarters.
  • Ergoteles's SpringWorks Therapeutics position peaked at $557K in Q1 2023.
  • 147 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.